EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Olaparib in treatment‐refractory isocitrate dehydrogenase 1 ( IDH1 )– and IDH2 ‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

Michael Cecchini iD, Mary Jo Pilat, Nataliya Uboha, Nilofer S Azad, May Cho, Elizabeth J Davis iD, Jordi Rodon Ahnert, Gabriel Tinoco, Geoffrey I Shapiro, Simon Khagi, Benjamin Powers, Kristen Spencer und 18 weitere

Cancer · 2025

DOI: 10.1002/cncr.35755 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2025. Verfasst von Michael Cecchini und 29 weiteren Autor:innen. Beteiligte Einrichtung: Yale University School of Medicine, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Phthalazines, Cholangiocarcinoma, Isocitrate Dehydrogenase, Piperazines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ben and Catherine Ivy Foundation, NCI NIH HHS, Rising Tide Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neomorphic isocitrate dehydrogenase ( IDH ) mutations lead to the accumulation of 2‐hydroxyglutarate (2‐HG), an oncometabolite implicated in tumor progression via inhibitory effects on alpha‐ketoglutarate. Moreover, mutant IDH –dependent accumulation of 2‐HG results in homologous recombination deficiency (HRD), which preclinically renders tumors sensitive to poly(adenosine diphosphate ribose) polymerase inhibitors. Here, the results of the cholangiocarcinoma (CCA) arm of the National Cancer Institute (NCI) 10129 olaparib in IDH ‐mutant solid tumors basket trial are reported.

Methods

Olaparib 300 mg twice daily was evaluated in an open‐label, phase 2 clinical trial for treatment‐refractory IDH ‐mutant solid tumors. Patients in the IDH ‐mutant CCA arm enrolled in two cohorts: (1) IDH inhibitor (IDHi) pretreated and (2) IDHi untreated, with a primary end point of overall response rate.

Results

NCI 10129 enrolled 30 patients with IDH ‐mutant CCA with no objective responses seen, and recruitment was closed early. Median progression‐free survival (PFS) was 2.4 months (95% CI, 1.9 to 6.5 months) and median overall survival was 12.9 months (95% CI, 6.3 months to not reached). Eight patients (27%) had clinical benefit (CB), with a PFS of ≥6 months. Patients with CB had lower baseline 2‐HG levels compared to those without CB (1.4 vs. 5.9 µmol/L; p = .01).

Conclusions

Olaparib does not have sufficient single‐agent activity to warrant further development in IDH ‐mutant CCA. However, a subgroup of patients demonstrated CB, and exploratory analysis revealed this subgroup to be enriched for lower baseline 2‐HG levels. Future clinical trials leveraging the HRD properties of IDH mutations are warranted with enhanced patient selection and novel combination therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesCholangiocarcinomaIsocitrate DehydrogenasePiperazinesBile Duct NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsHumansFemaleMaleMiddle AgedAgedMutationAdultUnited StatesNational Cancer Institute (U.S.)Aged, 80 and overDrug Resistance, Neoplasm

Stichwörter der Autor:innen

DNA repaircholangiocarcinomaisocitrate dehydrogenase (IDH) mutationolaparibpoly(adenosine diphosphate ribose) polymerase (PARP) inhibitor

Substanzen

olaparibPhthalazinesIsocitrate DehydrogenasePiperazinesIDH1 protein, humanIDH2 protein, humanPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Yale University School of Medicine, New Haven, Connecticut, USA.
  • Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA.
  • University of Wisconsin, Madison, Wisconsin, USA.
  • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • University of California, Irvine, California, USA.
  • Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA.

ORCID-Profile: Michael Cecchini, Elizabeth J Davis, Diane Durecki, Percy Ivy, Derek Shyr

Förderung

  • Ben and Catherine Ivy Foundation
  • NCI NIH HHS
  • Rising Tide Foundation
  • National Cancer Institute

Zitieren

APA

Cecchini, M., Pilat, M. J., Uboha, N., Azad, N. S., Cho, M., Davis, E. J., Ahnert, J. R., Tinoco, G., Shapiro, G. I., Khagi, S., Powers, B., Spencer, K., Groisberg, R., Drappatz, J., Chen, L., Das, B., Bao, X., Li, J., Narayan, A., …, & LoRusso, P. M. (2025). Olaparib in treatment‐refractory isocitrate dehydrogenase 1 ( IDH1 )– and IDH2 ‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. https://doi.org/10.1002/cncr.35755

Vancouver

Cecchini M, Pilat MJ, Uboha N, Azad NS, Cho M, Davis EJ, et al. Olaparib in treatment‐refractory isocitrate dehydrogenase 1 ( IDH1 )– and IDH2 ‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial. Cancer. 2025. doi:10.1002/cncr.35755

BibTeX
@article{Cecchini2025,
  author = {Cecchini, Michael and Pilat, Mary Jo and Uboha, Nataliya and Azad, Nilofer S and Cho, May and Davis, Elizabeth J and Ahnert, Jordi Rodon and Tinoco, Gabriel and Shapiro, Geoffrey I and Khagi, Simon and Powers, Benjamin and Spencer, Kristen and Groisberg, Roman and Drappatz, Jan and Chen, Li and Das, Biswajit and Bao, Xun and Li, Jing and Narayan, Azeet and Vu, Dennis and Patel, Abhijit and Niger, Monica and Doroshow, Deborah and Durecki, Diane and Boerner, Scott A and Bindra, Ranjit and Ivy, Percy and Shyr, Derek and Shyr, Yu and LoRusso, Patricia M},
  title = {Olaparib in treatment‐refractory isocitrate dehydrogenase 1 ( IDH1 )– and IDH2 ‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35755}
}
Kostenlos starten →